Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome

Overview of attention for article published in Blood Advances, May 2023

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (86th percentile)
High Attention Score compared to outputs of the same age and source (81st percentile)

Mentioned by

twitter: 21 X users

Readers on

mendeley: 48 Mendeley

So far, Altmetric has seen 26 X posts from 21 X users, with an upper bound of 224,050 followers.

@TalhaBadarMD ENA also looked promising in the HMA-failure arm in IDH2 mutated MDS https://t.co/QI04yaOrjO

RT @ELShematology: In observance of Leukemia and Lymphoma Awareness Month, read selected @BloodAdvances article: ‘Targeted therapy with the…

RT @ELShematology: Read ‘Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome’ a t…

RT @sanamloghavi: Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome - PubMed #h…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 22 additional X posts.